Cannabinol Shows Mixed Results for Insomnia in First Rigorous Clinical Trial

300 mg CBN did not significantly change the primary outcome (WASO: -6.3 min, p=0.29) but improved subjective sleep quality (p=0.005), reduced sleep onset latency (p=0.004), increased N2 sleep (p=0.03), and reduced EEG arousal indices (p=0.02). The 30 mg dose showed no significant effects.

Randomized, double-blind, placebo-controlled, three-arm, single-night crossover trial in 20 adults with physician-diagnosed insomnia disorder (ISI ≥15). Participants received single doses of 30 mg CBN, 300 mg CBN, or placebo with 2-week washout, measured by overnight polysomnography.

CBN is heavily marketed as a sleep aid despite virtually no clinical evidence. This first rigorous trial shows it has some real effects on sleep architecture and subjective quality, but doesn't meet the primary bar of reducing nighttime wakefulness.

The CBN sleep market is booming based on anecdote and marketing. This trial provides the first objective evidence — and the picture is more nuanced than industry claims suggest. CBN may help some aspects of sleep without being a cure-all for insomnia.

Very small sample (20 participants). Single-night assessment doesn't capture effects of repeated use. 17 of 20 participants were female, limiting generalizability. High adverse event count across all arms. 300 mg is a very high dose rarely found in consumer products.